Intravitreal Bevacizumab for Retinal Disorders

Sponsor
Narayana Nethralaya
Study ID
NCT00403026
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.

Key Dates

First listed
Nov 23, 2006
Start date
Aug 31, 2006
Status verified
Nov 2006
Completion
Nov 30, 2006

Study Design

Enrollment
150 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Vision change

Central Contacts

Related Studies